PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
Turnover
32.23%
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+43.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.56B
AUM Growth
+$116M
(+3.4%)
Cap. Flow
-$205M
Cap. Flow
% of AUM
-5.76%
Top 10 Holdings %
Top 10 Hldgs %
45.81%
Holding
127
New
13
Increased
20
Reduced
25
Closed
31
Avg Time Held Equity + Options
2.1
years
Top 10 Avg Time Held Equity + Options
1.5
years
Top 20 Avg Time Held Equity + Options
1.5
years
Avg Time Held Equity only
2.2
years
Top 10 Avg Time Held Equity only
1.5
years
Top 20 Avg Time Held Equity only
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$79.7M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$45.9M |
| 3 |
Vaxcyte
PCVX
|
+$45.9M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
+$39.2M |
| 5 |
Acrivon Therapeutics
ACRV
|
+$38.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$158M |
| 2 |
Relmada Therapeutics
RLMD
|
+$88.2M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$43.3M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$38.4M |
| 5 |
Edwards Lifesciences
EW
|
+$27.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.34% |
| 2 | Miscellaneous | 2.57% |
| 3 | Financials | 0.08% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Veru
VERU
$37M
| $41.5M | 1.17% |
785,801
+396,501
| +102% | +$32.6M |
2018 Q3
17 quarters
|
|
|
ALBO
27
DELISTED
Albireo Pharma Inc
ALBO
| $38M | 1.07% |
1,757,160
-602,979
| -26% | -$12.7M |
2017 Q2
22 quarters
|
|
28
Cogent Biosciences
COGT
$4.85B
| $37.1M | 1.04% |
3,207,441
| – | – |
2020 Q3
9 quarters
|
|
29
Viridian Therapeutics
VRDN
$2.09B
| $35.7M | 1% |
1,220,575
| – | – |
2021 Q2
6 quarters
|
|
30
DELISTED
RAPT Therapeutics
RAPT
| $35.6M | 1% |
224,869
+10,727
| +5% | +$1.72M |
2020 Q4
8 quarters
|
|
31
Zymeworks
ZYME
$1.78B
| $35.5M | 1% |
4,511,275
+111,176
| +3% | +$781K |
2017 Q2
22 quarters
|
|
|
32
Acrivon Therapeutics
ACRV
$74.1M
| $34.7M | 0.97% |
+3,007,858
| New | +$38.2M |
2022 Q4
0 quarters
|
|
33
Establishment Labs
ESTA
$1.72B
| $32.7M | 0.92% |
497,857
-80,396
| -14% | -$4.86M |
2018 Q3
17 quarters
|
|
34
DELISTED
Astria Therapeutics
ATXS
| $32.6M | 0.92% |
2,189,462
+908,265
| +71% | +$9.37M |
2021 Q1
7 quarters
|
|
|
CINC
35
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $31.7M | 0.89% |
2,576,325
-730,324
| -22% | -$17.4M |
2022 Q1
3 quarters
|
|
36
Immatics
IMTX
$1.04B
| $30.4M | 0.85% |
3,491,500
+991,500
| +40% | +$10.3M |
2020 Q3
9 quarters
|
|
37
Relay Therapeutics
RLAY
$3.74B
| $29M | 0.82% |
1,943,097
| – | – |
2020 Q3
9 quarters
|
|
38
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $28.7M | 0.81% |
182,935
| – | – |
2020 Q2
10 quarters
|
|
39
Outset Medical
OM
$72.2M
| $28.1M | 0.79% |
72,628
-5,281
| -7% | -$1.49M |
2020 Q3
9 quarters
|
|
40
Harmony Biosciences
HRMY
$2.2B
| $22.7M | 0.64% |
411,804
| – | – |
2022 Q2
2 quarters
|
|
41
Rocket Pharmaceuticals
RCKT
$243M
| $21.1M | 0.59% |
1,078,204
+578,204
| +116% | +$10.6M |
2018 Q4
16 quarters
|
|
42
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $20.4M | 0.57% |
1,744,500
| – | – |
2015 Q1
31 quarters
|
|
43
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $19.9M | 0.56% |
2,483,619
| – | – |
2021 Q2
6 quarters
|
|
44
DELISTED
Akero Therapeutics
AKRO
| $19.2M | 0.54% |
350,525
-79,475
| -18% | -$3.41M |
2022 Q3
1 quarter
|
|
45
Tarsus Pharmaceuticals
TARS
$3.42B
| $19M | 0.53% |
1,296,416
| – | – |
2020 Q4
8 quarters
|
|
46
Solid Biosciences
SLDB
$597M
| $18.8M | 0.53% |
3,495,933
+2,601,763
| +291% | +$17.1M |
2020 Q2
10 quarters
|
|
47
Nautilus Biotechnolgy
NAUT
$265M
| $16.4M | 0.46% |
9,111,151
| – | – |
2021 Q2
6 quarters
|
|
48
Roivant Sciences
ROIV
$24.3B
| $15.8M | 0.44% |
+1,981,570
| New | +$11M |
2022 Q4
0 quarters
|
|
49
LeonaBio Inc
LONA
$55.8M
| $15.2M | 0.43% |
479,728
| – | – |
2020 Q3
9 quarters
|
|
50
Prothena Corp
PRTA
$432M
| $14.3M | 0.4% |
237,646
+7,646
| +3% | +$448K |
2022 Q3
1 quarter
|
|
Similar funds
QP
RWM
AWA
WHRC
KGA
LSERS
CAG
MCM
Perceptive Advisors's Q4 2022 Portfolio in Review
As of Q4 2022, Perceptive Advisors held 127 positions worth $3.56B, up 3.4% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Perceptive Advisors withdrew a net $205M in Q4 2022, closing 31 positions and reducing 25 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Perceptive Advisors opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $109M.
- Perceptive Advisors's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 960,000 shares worth $109M.
- Perceptive Advisors added most to Sarepta Therapeutics in Q4 2022, an estimated $45.9M increase.
- Perceptive Advisors's biggest Q4 2022 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $38.4M.
- Perceptive Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $158M.
- Perceptive Advisors's ten largest holdings make up 46% of its $3.56B portfolio in Q4 2022.
- Perceptive Advisors opened 13 new positions and closed 31 in Q4 2022.
- Perceptive Advisors's portfolio value rose 3.4% quarter-over-quarter to $3.56B.
Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.